Opinion|Videos|February 11, 2025
Systemic Treatment Options for Atopic Dermatitis
Author(s)Raj Chovatiya, MD, PhD, MSCI
The panelist discusses how systemic atopic dermatitis (AD) treatment involves biologics and Janus kinase inhibitors for moderate to severe cases, targeting inflammation and itch with individualized approach based on patient factors, offering significant symptom improvement and skin barrier restoration.
Advertisement
Episodes in this series
Video content above is provided by the following:
- Describe your approach to initiating systemic treatment in patients with AD. At what point do you consider systemic treatment for your patients?
- Does your approach differ based on patient age or other factors?
- Briefly discuss the systemic agents that are currently FDA-approved for AD, including how they work to address itch and skin lesions, as well as efficacy and safety data.
- Dupilumab, lebrikizumab, tralokinumab, nemolizumab
- Abrocitinib, upadacitinib
Newsletter
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.
Advertisement
Related Content
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Dermatology Times
1
Icotrokinra Shows Superior Efficacy Over Advanced Oral Therapies in New Psoriasis Meta-Analysis
2
AbbVie Files for Vitiligo Indication, Putting Systemic Therapy Under Regulatory Review
3
Nutrafol Expands Portfolio with First and Only Hair Loss Supplement for Male Patients 50 and Older
4
Introducing Dermatology Times NP/PA Connect
5